BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27816965)

  • 1. Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.
    Li B; Yao Z; Wan Y; Lin D
    Oncotarget; 2016 Nov; 7(47):77342-77347. PubMed ID: 27816965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
    Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
    Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
    Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
    Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
    Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
    Emdad L; Lebedeva IV; Su ZZ; Gupta P; Sarkar D; Settleman J; Fisher PB
    J Cell Physiol; 2007 Feb; 210(2):549-59. PubMed ID: 17111370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin.
    Li K; Mo C; Gong D; Chen Y; Huang Z; Li Y; Zhang J; Huang L; Li Y; Fuller-Pace FV; Lin P; Wei Y
    Cancer Lett; 2017 Aug; 400():194-202. PubMed ID: 28259822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
    Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
    Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
    Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Liu Y; Wang S; Dong QZ; Jiang GY; Han Y; Wang L; Wang EH
    Med Oncol; 2016 Mar; 33(3):22. PubMed ID: 26820570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
    Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.
    Wang YT; Pan SH; Tsai CF; Kuo TC; Hsu YL; Yen HY; Choong WK; Wu HY; Liao YC; Hong TM; Sung TY; Yang PC; Chen YJ
    Sci Rep; 2017 Mar; 7():44021. PubMed ID: 28290473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.